This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Combination of TLR agonist and miR146a mimics attenuates ovalbumin-induced asthma
Molecular Medicine Open Access 29 June 2020
-
Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity
Scientific Reports Open Access 23 May 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Drugmakers cling to dual IL-13/IL-4 blockbuster hopes. Nat Biotechnol 36, 3–5 (2018). https://doi.org/10.1038/nbt0118-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0118-3
This article is cited by
-
Combination of TLR agonist and miR146a mimics attenuates ovalbumin-induced asthma
Molecular Medicine (2020)
-
Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity
Scientific Reports (2019)